OSI Pharmaceuticals, Inc. Release: Tarceva(R) (erlotinib) Endorsed by the U.K.’s National Institute for Clinical Excellence (NICE) for Use in Patients with Advanced Non-Small Cell Lung Cancer

MELVILLE, N.Y.--(BUSINESS WIRE)--OSI Pharmaceuticals, Inc. (Nasdaq: OSIP) welcomes today’s announcement by the U.K.’s National Institute for Health and Clinical Excellence (NICE) issuing Final Guidance recommending funding by the National Health Service (NHS) for Tarceva® (erlotinib) as an alternative treatment to the IV chemotherapy agent docetaxel for the second-line treatment of advanced non-small cell lung cancer (NSCLC). Tarceva is the first EGFR targeted agent for advanced NSCLC recommended for use by NICE.

Back to news